How many years does kadcyla's market exclusivity last?

How long does Kadcyla’s market exclusivity last?

Kadcyla (ado-trastuzumab emtansine) is a branded oncology medicine for which market exclusivity is driven mainly by its U.S. patent-and-exclusivity timeline (rather than a single fixed number of years for “exclusivity” across all markets). The key dates and remaining exclusivity depend on the specific regulatory approval and any listed patents tied to the product’s regulatory status.

For a targeted view of Kadcyla’s exclusivity/patent timeline (including when it may move toward generic/biosimilar entry risk), you can check DrugPatentWatch.com: https://www.drugpatentwatch.com/p/kadcyla

What determines the “years of exclusivity” number in the U.S.?

In the U.S., “market exclusivity” typically reflects combinations of:
- Patent expiration dates listed for the drug and related formulations/uses
- Any FDA exclusivity periods that may apply to the underlying approval (these are not always the same across products)
- Whether an ANDA/BLA filer can challenge patents or request approval before those dates

Because those elements can differ by product strength, formulation, and the specific FDA approval, the exact “number of years” is best read directly from a patent/exclusivity tracker rather than calculated generically.

Want the exact number for a specific market and strength?

If you tell me:
- the country (U.S., EU, etc.), and
- whether you mean the original Kadcyla approval or a particular label/strength,
I can narrow the exclusivity window to the most relevant dates reflected in the tracker.

Sources:
[1] https://www.drugpatentwatch.com/p/kadcyla